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Abstract: Androgen receptor antagonists have been proved to be effective anti-prostate 
cancer agents. 3D-QSAR and Molecular docking methods were performed on curcumin 
derivatives as androgen receptor antagonists. The bioactive conformation was explored by 
docking the potent compound 29 into the binding site of AR. The constructed Comparative 
Molecular  Field  Analysis  (CoMFA)  and  Comparative  Similarity  Indices  Analysis 
(CoMSIA)  models  produced  statistically  significant  results  with  the  cross-validated 
correlation coefficients q
2 of 0.658 and 0.567, non-cross-validated correlation coefficients 
r
2  of  0.988  and  0.978,  and  predicted  correction  coefficients  r
2
pred  of  0.715  and  0.793, 
respectively. These results ensure the CoMFA and CoMSIA models as a tool to guide the 
design of novel potent AR antagonists. A set of 30 new analogs were proposed by utilizing 
the results revealed in the present study, and were predicted with potential activities in the 
developed models. 
Keywords:  CoMFA;  CoMSIA;  docking;  androgen  receptor  antagonists;  curcumin 
derivatives 
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1. Introduction 
Prostate cancer is the most common malignant tumor and the second most common cause of cancer 
death in the male population [1]. The current treatment for prostate cancer is a combination of surgery, 
radiation,  and  chemotherapy  [2].  As  prostate  cancer  development  and  disease  progression  is  
hormone dependent, blockade of androgen action is the foundation of most popular therapies  [3]. 
Castration-resistant prostate cancer (CRPC) is an advanced status of prostate cancer associated with 
high death rates [4]. Treatment options for CRPC are an unmet need, with current anti-androgens 
having been shown only to prolong survival [5]. The androgen receptor (AR) is postulated to play a 
key  mediator  of  prostate  cancer  [6].  Over  the  past  2  decades,  several  important  mechanisms  of 
mutation in AR have been elucidated. Laboratory observations have offered clues that AR mutations 
have  turned  the  growth-inhibitory  effect  of  the  current  clinically  used  anti-androgens  into  a  
growth-promoting effect at the castration-resistant form [5,6]. This has led to an attractive strategy 
targeting mutant AR which offer promising potential in future treatment of CRPC. 
In recent years, a number of androgen receptor antagonists have appeared, among them, Li Lin et al. 
synthesized a series of curcumin derivatives as potent selective AR antagonists. Some compounds 
showed significant cytotoxicity against human prostate cancer cell lines, androgen-dependent LNCaP. 
Anti-androgenic  activity  was  also  evaluated  in  LNCaP  cells  transfected  with  wild-type  AR  [2].  
In  addition,  the  X-ray  crystal  structures  of  AR  have  been  determined  [7]  which  provide  useful 
information about the interaction with the residues near the binding site. 
The three dimensional quantitative structure activity relationships (3D-QSAR) may be useful in 
drug discovery and design [8]. As the most popular QSAR methods, Comparative Molecular Field 
Analysis  (CoMFA)  [9]  and  Comparative  Similarity  Indices  Analysis  (CoMSIA)  [10]  studies 
incorporate  3D  information  for  the  ligands  by  searching  for  sites  on  molecules  capable  of  being 
modified into better specific ligands. As a useful methodology for studying the interaction mechanism, 
receptor based molecular docking analysis can offer vivid interaction picture between a ligand and an 
acceptor [11]. Combined 3D-QSAR and docking study could offer more information to understand the 
structural features of bonding site of protein and the detail of protein–ligand interactions for purposive 
directing the design of new potential molecules [12]. 
In this work, QSAR and docking studies of androgen receptor antagonists with anticancer activity 
against human prostate cancer cell line LNCaP were carried out. An optimal 3D QSAR model for 
these compounds was established, and the model can be used to predict quantitatively the properties of 
entry antagonists not in the data set. We expect that the results can offer some reference to guide the 
design of novel potent AR antagonists. 
2. Material and Methods 
2.1. Data Sets 
All curcumin derivatives and their biological activities (IC50 values) were taken from the literature [2]. 
In  order  to  examine  the  predictive  ability  and  robustness  of  the  QSAR  models,  the  test  set  of  
7 molecules were selected randomly in such a way that the structural diversity and wide range of Int. J. Mol. Sci. 2012, 13  6140 
 
 
activity in the data set were included, and the remaining 33 compounds are treated as a training set and 
used to derive the 3D-QSAR models. 
The structures of the compounds and their biological data are given in Table 1. The cytotoxicity 
bioassay was performed according to the procedures described in Lin et al. [2]. IC50 values are mean 
concentrations that inhibit growth by 50% and variation between replicates was less than 5%. The IC50 
values in units of μM were transformed in pIC50 (-log IC50) in order to give numerically larger  
data values. 
Table 1. Structures and experimental anticancer activities (against human prostate cancer 
cell line LNCaP) of the curcumin derivatives. 
R2
R3
R1 OH
R5
O
R4 (I) 
Compound  R1  R2  R3  R4  R5  IC50 (μM)  pIC50 
1  H  OMe  OH  H  H  6.2  5.208 
2  H  OMe  OMe  H  H  6.6  5.180 
3 *  H  OH  OMe  H  H  5.3  5.276 
4  OMe  H  OMe  H  H  9.9  5.004 
5  OMe  OMe  OMe  H  H  5.8  5.237 
6  H  OMe  OMe  OMe  H  12.5  4.903 
7  H  OMe  OH  H  (CH2)2COOEt  51.5  4.288 
O OH
X O
H3C
HO
R1
(II) 
Compound  R1  X  IC50 (μM)  pIC50 
8  CH2OH  O  7.3  5.137 
9  H  S  6.3  5.201 
10*  H  NH  13.6  4.866 
O OH R1
R2
R3 R4
R5
R1
R2
R3 R4 (III) 
Compound  R1  R2  R3  R4  R5  IC50 (μM)  pIC50 
11  H  OMe  OH  H  H  3.8  5.420 
12  H  OMe  OMe  H  H  1.3  5.886 
13  H  OMe  OH  H  (CH2)2COOEt  1.5  5.824 
14  H  OH  OMe  H  H  10.9  4.963 
15  OMe  H  OMe  H  H  11.8  4.928 
16  OMe  OMe  OMe  H  H  4.8  5.319 
17  H  OMe  OMe  OMe  H  2.9  5.538 
18 *  H  OMe  OTHP  H  (CH2)2COOEt  4.2  5.377 
19  H  OMe  OEt  H  H  6.5  5.187 
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Table 1. Cont. 
20 
O OH
H3CO
HO
OCH3
OH
OCH3 OCH3  
2.6  5.585 
21  H  Me  OH  H  H  1.8  5.745 
22  H  Me  OMe  H  H  7.7  5.114 
O OH
H3CO
H3CO
R5
R1
R2
R3 R4 (IV) 
Compound  R1  R2  R3  R4  R5  IC50 (μM)  pIC50 
23  H  OMe  OH  H  H  3.3  5.481 
24  H  OH  OMe  H  H  4.8  5.319 
25  OMe  OMe  OMe  H  H  7.7  5.114 
26 *  H  OMe  OMe  OMe  H  8.6  5.066 
27  H  OMe  OH  H  (CH2)2COOEt  2.1  5.678 
X H3CO
R1
OCH3
R1 (V) 
Compound  R1  X  IC50 (μM)  pIC50 
28 *  OH 
OH
(CH2)2COOEt
O
  
3.1  5.509 
29  OMe 
OH
HC
O
CHCOOEt 
0.2  6.699 
30  OTHP 
OH
HC
O
CHCOOEt 
2.6  5.585 
31 *  OMe 
N
H
O O
 
2.2  5.658 
32  OMe 
OH
HC
O
CHCOOMe 
0.4  6.398 
33  OMe 
OH
HC
O
CHC(=O)NHEt 
0.6  6.222 
34 *  OMe 
OH
HC
O
CHCN 
0.2  6.699 
35  OH 
OH
C
O
O  
8.8  5.056 
36  OTHP 
O O
F (CH2)2COOEt 
7.3  5.137 
37  OH 
O O
F (CH2)2COOEt 
6.3  5.201 
38  OMe 
O
  3.4  5.469 
39  OH 
OH O
 
4.4  5.357 
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Table 1. Cont. 
40  OMe 
OH
HC
O
CHCH2OH 
0.2  6.699 
* Compounds taken for the test set. 
2.2. Molecular Modeling and Alignment 
All  molecular  modeling  and  3D-QSAR  calculations  were  done  using  SYBYL  X  1.3  (Tripos 
Associates Inc., St. Louis, Missouri, USA, 2011). Molecular building was done with a molecule sketch 
program on the same software. The molecular geometry of each compound was first minimized using 
a standard Tripos molecular mechanics force field with 0.01 kcal/(mol Å) energy gradient convergence 
criterion.  Partial  atomic  charges  were  calculated  by  the  Gasteiger-Hü ckel  method  and  energy 
minimizations were performed using the Powell method 1000 iterations [13]. 
The accuracy of the prediction of QSAR model and reliability of the contour maps are directly 
dependent  on  the  structural  alignment  rule  [14].  In  order  to  obtain  the  best  possible  3D-QSAR 
statistical model, two different alignment rules were adopted. During the process, the lowest energy 
conformation of compound 29 was used as the template for the alignment, because it is one of the most 
active compounds in Table 1. Figure 1a describes the common substructure for the alignment which is 
marked in bold. However, due to with no such substructure of Figure 1a in the structures, compounds 
1–10, 28 and 31 were aligned based on another common substructure depicted in bold as shown in 
Figure 1b,c shows the resulting ligand-based alignment model. 
Figure 1. Molecular alignment of the compounds in the training set. 
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2.3. CoMFA and CoMSIA Field Calculation 
The  standard  CoMFA  procedure  as  implemented  by  SYBYL  X  1.3  was  performed.  For  each 
aligned sets of molecules were positioned inside a 3D cubic lattice with a grid spacing of 2.0 Å 
(default distance) in all Cartesian directions was generated to enclose the molecule aggregate. A sp
3 
carbon atom with a charge of +1.0 and a van der Waals radius of 1.52 Å was used as a probe; this atom 
was placed at every lattice point to calculate various steric and electrostatic fields by the CoMFA 
standard  method  with  default  cut-off  energy  of  30.0  kcal/mol  [15].  In  order  to  reduce  noise  and 
improve efficiency, column filtering was set to 1.0 kcal/mol. The fields generated were scaled by 
CoMFA standard in SYBYL automatically. 
The CoMFA region focusing is the application of weights to the lattice points in a CoMFA region 
to enhance or attenuate the contribution of those points to subsequent analyses. When the weights are 
StDev*Coefficient  values,  the  process  is  exactly  equivalent  to  image  enhancement  of  the  derived 
CoMFA maps for getting the better models [16]. 
The CoMSIA method, discovered by Klebe [10], has advantages over CoMFA technique such as 
greater robustness regarding both region shifts and small shifts within the alignments [16]. With the 
standard parameters and no arbitrary cutoff limits, five fields associated, namely, steric, electrostatic, 
hydrophobic,  hydrogen  bond  donor  and  hydrogen  bond  acceptor,  were  calculated  using  the  same 
lattice box created for CoMFA. The default value of 0.3 was used as the attenuation factor. 
2.4. Partial Least Square Analysis 
The  partial  least  squares  (PLS)  methodology  was  used  to  derive  a  linear  relationship  for  the  
3D-QSAR, and cross-validation was performed using the leave-one-out(LOO) method [17] to choose the 
optimum number of components (ONC) and assess the statistical significance of each model. In PLS, the 
independent  variables  were  the  CoMFA  and  CoMSIA  descriptors,  and  pIC50  values  were  used  as 
dependent  variables  [16].  The  ONC  was  the  number  of  components  that  led  to  the  highest  
cross-validated correlated correlation coefficient q
2 (or r
2
cv). Before the PLS analysis, the CoMFA and 
CoMSIA  columns  were  filtered  by  using  column  filtering.  Non-cross-validation  was  performed  to 
calculate conventional r
2
ncv using the same number of components. To further assess the robustness and 
statistical confidence of the derived models, bootstrapping analysis for 100 runs was performed [9,18]. 
2.5. Molecular Docking 
To determine the probable binding conformations and offer more insight into the understanding of 
the interactions of androgen receptor antagonists, molecular docking analysis was carried out using the 
Surflex Dock in SYBYL. The crystal structure of AR was retrieved from RCSB Protein Data Bank 
(PDB entry code: 1T65) [7]. The protein structures were utilized in subsequent docking experiments 
without energy minimization. All ligands and water molecules have been removed at first, the polar 
hydrogen atoms and AMBER7FF99 charges were added. Protomol, a computational representation of 
the intended binding site, is used to guide molecular docking [19]. Jinming Z. et al. predicted binding 
mode  of  AR  antagonists  in  the  antagonistic  model  of  wild  type  AR  ligand-binding  domain  (WT  
AR-LBD). E709, Q738, W741, M742, L880, L881, and V889 were key residues of the active site to Int. J. Mol. Sci. 2012, 13  6144 
 
 
form hydrogen bonds or a hydrophobic pocket [6]. Therefore, the active sites were considered to be the 
potential receptor’s binding sites. In view of this, residues mode was adopted to generate the protomol 
by specifying residues in the receptor near Helix 12 in this study. The protomol bloat value was set as 
1 and the protomol threshold value as 0.5 when a reasonable binding pocket was obtained. Other 
parameters are established by default in software. 
3. Results and Discussion 
3.1. CoMFA and CoMFA Region Focusing 
The results of CoMFA studies are summarized in Table 2. The optimal number of components was 
determined  by  selecting  highest  q
2  value.  PLS  analysis  showed  a  high  q
2  value  of  0.564  with  6 
components for CoMFA. The non-cross-validated PLS analysis results in a conventional r
2
ncv of 0.986; 
F is 304.611, and a standard error of estimation (SEE) of 0.068. When these fields were focused, the q
2 
improved  and  produced  highest  q
2  of  0.658  with  6  components,  F  =  352.278,  r
2
ncv  =  0.989  and  
SEE = 0.063. The steric and electrostatic contributions were 48.8% and 51.2%, respectively. Bootstrap 
analysis for 100 runs was then carried out for further validation of the model by statistical sampling of 
the original data set to create new data sets. The higher r
2 bootstrap value 0.992 for CoMFA with 
standard  error  value  of  0.049  is  supporting  the  statistical  validity  of  the  developed  models.  The 
predicted activities for the antagonists versus their experimental activities are listed in Table 3 and the 
correlation between the predicted activities and the experimental activities is depicted in Figure 2. The 
predictive correlation coefficient r
2
pred was found to be 0.715 for the test set. Statistical results suggest 
that the CoMFA model is a reliable predictor. 
Table 2. Statistical quality parameters of different molecular interaction field methods. 
Component 
a  q
2 
b  r
2
ncv 
c  F 
d  SEE 
e 
A–CoMFA region focusing model in Gs = 1 in various numbers of components 
f 
1  0.306  0.533  35.367  0.357 
2  0.396  0.738  42.156  0.272 
3  0.501  0.893  80.916  0.176 
4  0.590  0.955  149.067  0.116 
5  0.629  0.978  237.429  0.083 
6  0.658  0.988  352.278  0.063 
B–CoMFA model in Gs = 2 in various numbers of components 
f 
1  0.209  0.395  23.191  0.395 
2  0.273  0.688  33.010  0.297 
3  0.399  0.881  71.577  0.186 
4  0.432  0.940  109.490  0.135 
5  0.526  0.976  223.159  0.086 
6  0.564  0.986  304.611  0.068 
a Optimum number of components (ONC) obtained from cross-validated PLS analysis and same used in final 
non-cross-validated  analysis; 
b  q
2:  Cross-validated  correlation  coefficient; 
c  r
2
ncv:  Non-cross-validated 
correlation coefficient; 
d F: F-test value; 
e SEE: Standard error of estimate; 
f Column filtering = 1.0 kcal/mol.  
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Table 3. Comparative Molecular Field Analysis (CoMFA)/Comparative Similarity Indices 
Analysis (CoMSIA) predicted activity (PIC50) of compounds. 
Compound 
Predicted 
Activity 
(CoMFA) 
Predicted 
Activity 
(CoMSIA) 
Compound 
Predicted 
Activity 
(CoMFA) 
Predicted 
Activity 
(CoMSIA) 
1  5.191  5.124  21  5.684  5.634 
2  5.163  5.257  22  5.115  5.187 
3 *  4.963  4.896  23  5.526  5.554 
4  4.971  4.935  24  5.255  5.249 
5  5.277  5.202  25  5.157  5.115 
6  4.900  4.964  26 *  5.412  5.260 
7  4.323  4.333  27  5.642  5.747 
8  5.145  5.144  28 *  5.540  5.389 
9  5.208  5.242  29  6.580  6.606 
10 *  5.264  5.243  30  5.559  5.697 
11  5.463  5.495  31 *  6.039  5.800 
12  5.929  5.925  32  6.543  6.543 
13  5.763  5.850  33  6.347  6.169 
14  5.003  4.960  34 *  6.407  6.487 
15  4.929  4.879  35  5.013  5.072 
16  5.281  5.325  36  5.094  5.062 
17  5.522  5.567  37  5.290  5.186 
18 *  5.235  5.175  38  5.507  5.567 
19  5.167  5.020  39  5.337  5.353 
20  5.589  5.586  40  6.603  6.529 
* Compounds taken for the test set. 
Figure 2. Correlation between the experimental and CoMFA (region focusing) predicted 
activities of compounds. 
 
3.2. CoMSIA 
The PLS results of CoMSIA analysis using different combinations were depicted in Table 4. The 
SEHD field descriptors exhibited highest q
2, better SEE and F values than the others. Therefore, the 
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combination of steric (S), electrostatic (E), hydrophobic (H) and hydrogen bond donor (D) fields was 
selected as the best model. The CoMSIA model gave a q
2 of 0.567 with an optimized component 
number of 5. A high r
2
ncv of 0.978 with a low SEE of 0.083 and F value of 241.534. High values of the 
electrostatic (43.0%) and hydrogen bond donor (23.6%) fields show the importance of the electrostatic 
and hydrogen bond donor nature of the substituents on the core. The other descriptors, steric (16.0%) 
and the hydrophobic (17.3%) also have contribution. The predicted activities for the antagonists versus 
their experimental activities are listed in Table 3 and the correlation between the predicted activities 
and the experimental activities is depicted in Figure 3.The predictive correlation coefficient r
2
pred was 
found to be 0.793 for the test set. Bootstrap analysis for 100 runs was then carried out for further 
validation of the model by statistical sampling of the original data set to create new data set. This r
2 of 
bootstrap  value  is  0.983  for  CoMSIA  with  standard  error  value  of  0.069,  supporting  further  the 
statistical validity of the developed models. All the results indicate that the CoMSIA model is also 
fairly predictive. 
Table 4. Regression summary of CoMFA and CoMSIA models. 
              Field Contribution in % 
Descriptors  ONC  q
2  r
2
ncv  r
2
pred 
a  SEE  F  S  E  H  D  A 
CoMFA                       
SE  6  0.658  0.988  0.715  0.063  352.278  48.8  51.2  －  －  － 
CoMSIA 
b                       
SE  5  0.498  0.967    0.102  156.626  27.2  72.8  －  －  － 
SHE  6  0.536  0.985    0.069  292.088  19.6  57.6  22.7  －  － 
SED  6  0.519  0.983    0.075  247.310  22.3  52.0  －  25.7  － 
SEA  5  0.404  0.965    0.105  148.070  19.7  55.0  －  －  25.3 
SEHD  5  0.567  0.978  0.793  0.083  241.534  16.0  43.0  17.3  23.6  － 
SEDA  5  0.486  0.969    0.098  170.503  15.6  38.9  －  23.5  21.9 
SEHA  6  0.426  0.983    0.074  255.498  15.3  45.9  17.8  －  20.9 
SEHDA  6  0.514  0.983    0.074  250.217  12.7  33.4  14.3  21.6  18.0 
a r
2
pred: Predictive r
2; 
b Field contributions: Steric (S) and electrostatic (E) field from CoMFA; Steric (S), 
electrostatic (E), hydrophobic (H), donor (D), and acceptor (A) fields from CoMSIA. 
Figure  3.  Correlation  between  the  experimental  and  CoMSIA  predicted  activities  
of compounds. 
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3.3. Contour Maps Analysis 
The best CoMFA and CoMSIA models are selected to construct the stdev*coeff contour maps to 
view the field effects on the target features. All the contours represented the default 80% and 20% 
level contributions for favorable and unfavorable regions, respectively, except 70% and 30% level 
contributions  in  figure  of  hydrogen  bond  donor  contour  maps.  The  maps  showed  regions  where 
differences in molecular fields are associated with differences in biological activity. 
3.3.1. CoMFA Contour Maps 
CoMFA steric contour maps are shown in Figure 4. The steric interaction is represented by green 
and yellow contours, while electrostatic interaction is denoted by red and blue contours. A large green 
contour was found near the substituent group of C-4 position indicating that bulky substituents were 
preferred in this region (Figure 4a). This may be the reason why compounds with alkyl substituents in 
this  area, e.g., compounds  32, 33 and 40, are more potent AR  antagonist activity than molecules 
without any substituent at this particular position, such as compounds 14, 15 (Figure 4a) and 22. 
Figure 4. CoMFA steric contour maps for compounds: (a) compound 29; (b) compound 15. 
 
The CoMFA electrostatic contour plots for compounds are displayed in Figure 5. The blue contours 
indicate that electropositive substituents would increase the AR antagonist activity with protein, while 
red color indicates that they should be the electron rich groups [18]. Since the red contours were found 
near the methoxyl group of compounds 29, which is an electron rich functionality, compounds 29 exhibit 
high AR antagonist activity (Figure 5a). A large blue contour was found near the methoxyl substituent 
on phenyl ring of compound 7 (Figure 5b), indicating that negatively charged groups are disfavored at 
this position, and that is a possible reason why compound 7 displays less potent AR antagonist activity 
than compound 29. 
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Figure  5.  CoMFA  electrostatic  contour  maps  for  compounds:  (a)  compound  29;  
(b) compound 7. 
 
3.3.2. CoMSIA Contour Maps 
The CoMSIA contour maps, derived using steric, electrostatic, hydrophobic and hydrogen bond 
donor fields, are represented in Figures 6–9. CoMSIA steric and electrostatic contours are more or less 
similar to those of the CoMFA. As in case of CoMFA, a large green contour was found overlapping 
the substituent group of C-4 position (Figure 6a), to indicate that bulky substituents were preferred in 
this region compared with compound 15 (Figure 6b). 
Figure 6. CoMSIA steric contour maps for compounds: (a) compound 29; (b) compound 15. 
 
Figure 7 shows the CoMSIA electrostatic fields denoted by red and blue contours. Red contours 
represent regions where negatively charged substituents are preferred on ligands and blue contours 
indicate regions where electron-rich substituents are unfavorable for the activity. The methoxyl groups 
of compound 29 are all near the red areas (Figure 7a), the favored position for electronegative groups. 
While one the methoxyl groups of compounds 15 is near the blue contour, which means that this group 
is not favored in this region and will lead to a decrease in the AR antagonist activity (Figure 7b).  
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Figure  7.  CoMSIA  electrostatic  contour  maps  for  compounds:  (a)  compound  29;  
(b) compound 15. 
 
Figure 8 shows the hydrophobic contour maps in which yellow and gray contours indicate the 
regions where hydrophobic and hydrophilic groups are favored by the model, respectively. A yellow 
contour  overlapping  the  linker  including  aliphatic  hydrocarbon  structure  of  compound  21  group 
indicates  that  hydrophobic  substituent  at  this  position  would  increase  the  AR  antagonist  activity 
(Figure 8a). The two large gray contours near the hydroxyl groups indicate that hydrophilic groups at 
these positions are favorable. These results are quite similar to those of compound 29 (Figure 8b). 
Figure  8.  CoMSIA  hydrophobic  contour  maps  for  compounds:  (a)  compound  21;  
(b) compound 29. 
 
Hydrogen-bond  donor  contour  maps  from  CoMSIA  are  shown  in  Figure  9.  Here,  the  maps 
generated depict regions  having scaled coefficients  70% (favored) or 30% (disfavored). The  cyan 
contours represent the regions where hydrogen bond-donating groups increase the activity; the purple 
contours represent the regions where hydrogen bond-donating groups decrease the activity. As shown 
in Figure 9a, the cyan contours are near the H-bond donor, hydroxyl groups, of compound 21, whereas 
the  methoxy  groups  of  compound  29  are  present  near  the  purple  contour  (Figure  9b)  as  
H-bond acceptors. 
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Figure  9.  CoMSIA  hydrogen  bond  donor  contour  maps  for:  (a)  compound  21;  
(b) compound 29. 
 
3.4. Docking Analysis 
Docking was employed to explore the binding mode between these curcumin derivatives and the 
AR, to examine the stability of 3D-QSAR models previously established. We selected the most potent 
antagonist 29 in the experiment to perform the deeper docking study and discussion below. In order to 
visualize secondary structure elements, the MOLCAD program was applied. Figure 10a showed the 
secondary structure of the receptor. The key residues and hydrogen bonds were labeled. As shown in 
Figure 10a, the oxygen atom of methoxy group acted as a hydrogen bond acceptor by forming two  
H-bonds with the –NH2 group of the HIS920 residue and the –NH– group of the GLU893, respectively. 
The observations taken from Figure 10 were in agreement with the corresponding CoMSIA hydrogen 
bond contour maps. 
Figure 10. Binding conformations of the compound 29 at the bonding site of androgen 
receptor (AR). 
 
Figure 10b depicted the MOLCAD cavity depth potential surfaces structure of the binding site 
within the compound 29. The cavity depth color ramp ranges from blue (low depth values = outside of Int. J. Mol. Sci. 2012, 13  6151 
 
 
the pocket) to light red (high depth values = cavities deep inside the pocket) [20]. The substituent 
group of C-4 position of compound 29 was oriented in a light red region which demonstrated that this 
part was anchored deep inside the pocket. The remaining parts of compound 29 are found in the cyan 
area which indicated that the benzene ring was anchored outside the pocket. 
Figure 10c showed the MOLCAD lipophilic potential (LP) surface of the binding area, the color for 
LP ranges from brown (highest lipophilic area of the surface) to blue (highest hydrophilic area). The 
linker of molecule was oriented to a brown region, suggesting that a hydrophobic substituent may be 
favored; the methoxy group was oriented to the blue and white areas which indicated that a hydrophilic 
group would be favorable. The observations taken from Figure 10c satisfactorily matched those of the 
CoMSIA hydrophobic contour map. 
Figure 10d displayed the MOLCAD hydrogen bonding sites of the binding surfaces, ligands can be 
docked to proteins by matching the patterns displayed on the surface, the red is hydrogen donors and 
the blue is hydrogen acceptors. As shown in Figure 10d, the methoxy groups were oriented to a red 
surface, which indicated that the surfaces of this site were hydrogen bond donors, and a hydrogen bond 
acceptor substituent would be favorable. The observations taken from this hydrogen bonding sites 
satisfactorily matched the corresponding CoMSIA hydrogen bond contour maps. 
3.5. Summary of Structure-Activity Relationship 
The  structure-activity  relationship  revealed  by  3D-QSAR  and  molecular  docking  studies  were 
illustrated in Figure 11. The negatively charged substituents, H-bond acceptors at R1, R2, R3, and R4 
position would increase the activity; the substitution at the C-4 position of the linker is very crucial for 
improved activity in this compound class. The hydrophobic substituent at the position of the linker 
would increase the activity. Biphenyl rings at the both two sides of curcumin derivatives are required 
for the cytotoxic same as those in bicalutamide, a known and clinically used AR antagonist. Here, the 
hydrophobic property of benzene ring plays a key role in the anti-androgenic activities. 
Figure 11. Summary of structure-activity relationship. 
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3.6. Designs for New Molecules 
Based on QSAR and docking results, antagonists 29, with the highest activity, was taken as  a 
template to design new compounds. A set of 30 new compounds with high predicted activity were 
designed and assessed (Table 5), these molecules were aligned to the database and their activities were 
predicted by the CoMFA and CoMSIA models previously established. The chemical structures and Int. J. Mol. Sci. 2012, 13  6152 
 
 
predicted pIC50 values of these compounds were shown in Table 5, and the graph of their predicted 
pIC50 values versus the most active compound 29 was shown in Figure 12. Most of the designed 
molecules exhibited better predicted pIC50 values than compound 29 in CoMFA or CoMSIA models. 
Molecules D2, D3, D7, D9-14, D17, D19-20, D23-24, and D27-30 displayed significantly improved 
predicted activities than compound 29 in both the CoMFA and CoMSIA models. The results validated 
the structure activity relationship obtained by this study. 
Table 5. The structures and predicted pIC50 values of newly designed derivatives. 
O O
O O
R1 R2
R3  
Compound ID 
Substituent  Predicted pIC50 
R1  R2  R3  COMFA  COMSIA 
29  OMe  OMe  CH=CHCOOEt  6.582  6.599 
D1  CN  CN  CH=CHCOOEt  6.817  6.583 
D2  SO3H  SO3H  CH=CHCOOEt  6.714  6.619 
D3  NO2  NO2  CH=CHCOOEt  6.696  6.876 
D4  CF3  CF3  CH=CHCOOEt  6.651  6.544 
D5  COOH  COOH  CH=CHCOOEt  6.293  6.840 
D6  CHO  CHO  CH=CHCOOEt  6.691  6.506 
D7  Br  Br  CH=CHCOOEt  6.783  6.583 
D8 
N
N
N
H
N
  N
N
N
H
N
 
CH=CHCOOEt  6.773  6.196 
D9  NO2  CN  CH=CHCOOEt  6.774  6.666 
D10  B(OH)2  B(OH)2  CH=CHCOOEt  6.664  6.571 
D11  CN   CN  CH=CH(CH2)3CH3  6.680  6.585 
D12  OMe  OMe 
S N
N
 
6.648  6.727 
D13  OMe  OMe 
S N
N
 
6.662  6.832 
D14  OMe  OMe 
S N  
6.670  6.740 
D15  OMe  OMe 
N N
NH N
 
6.518  6.802 
D16  OMe  OMe 
N N
N N
 
6.526  6.864 
D17  CN  CN 
S N
N
 
6.798  6.670 
D18  CN  CN 
S N
N
 
6.787  6.787 
D19  NO2  NO2 
S N
N
 
6.828  6.973 
D20  NO2  NO2 
S N
N
 
6.813  7.094 
D21  COOH  COOH 
S N
N
 
6.020  6.917 Int. J. Mol. Sci. 2012, 13  6153 
 
 
Table 5. Cont. 
Compound ID 
Substituent  Predicted pIC50 
R1  R2  R3  COMFA  COMSIA 
D22  COOH  COOH 
S N
N
 
6.112  7.058 
D23  CN  CN 
N N
NH N
 
6.804  6.783 
D24  CN  CN 
N N
N N
 
6.749  6.842 
D25  COOH  COOH 
N N
NH N
 
6.068  7.017 
D26  COOH  COOH 
N N
N N
 
6.053  7.084 
D27  NO2  NO2 
N N
NH N
 
6.789  7.119 
D28  NO2  NO2 
N N
N N
 
6.765  7.172 
D29 
N
N
H
N
  N
N
H
N
 
N N
N N
 
6.641  6.863 
D30  Br  Br 
N N
N N
 
6.794  6.746 
Figure 12. Graph of the predicted pIC50 of the designed molecules versus compound 29. 
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Figure 12. Cont. 
 
4. Conclusion 
In the present study, 3D-QSAR analyses have been applied to a set of curcumin derivatives. The 
models have proven to be statistically robust with higher q
2 and r
2. Also, as demonstrated in our study, 
3D-QSAR and docking methods were employed to understand the structural features responsible for 
the affinity of the ligands for AR. These results provided crucial clues that were used to design novel 
androgen receptor antagonists with high predicted potent activity. A set of 30 novel derivatives were 
designed by utilizing the structure-activity relationship taken from the present study. 
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